A Phase 1 interventional study of [14C]-GSK1278863 solution for IV infusion and [14C]-GSK1278863 oral solution in Anaemia, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-03.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 28th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 20th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 30 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 33rd largest by enrollment, is one of 4 that started in 2017, is one of 14 in phase 1, and was the 26th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Absorption, metabolism and excretion of daprodustat (GSK1278863) have been studied in previous clinical trials; however, the elimination routes and metabolic pathways of daprodustat have not been fully elucidated in humans. This is an open-label, single-center, non-randomized, 2-period, single-sequence, crossover, mass balance study in 6 healthy male participants. The aim of the study is to assess the excretion balance of daprodustat using [14C]-radiolabeled drug substance administered orally, and as an intravenous (IV) infusion, administered as a microtracer dose (concomitant with an oral, non-radiolabeled dose). Absolute bioavailability of an oral dose will also be assessed. Each participant will be involved in the study for up to 10 weeks which include a screening visit, two treatment periods (treatment periods 1 and 2), separated by about 7 days (at least 14 days between oral doses), and a follow up visit 1-2 weeks after the last assessment in treatment period 2. The primary objective of the study is to gain a better understanding of the compound's excretory and metabolic profile. This study will include sampling of duodenal bile to conduct qualitative assessment of drug metabolites in this matrix in order to characterize biliary elimination pathways.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of \[14C\]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg \[14C\]-GSK1278863 as an oral solution.
Drug: [14C]-GSK1278863 solution for IV infusion · Drug: [14C]-GSK1278863 oral solution · Drug: Daprodustat 6 mg oral tablet
It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
It is a 9.0 millimeter (mm) round, white film coated tablet.
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
T1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Vss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
CL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration.
Time frame: Pre-dose and then over 24 hours collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120,120-144 and 144-168 hours post-dose in treatment period 2
Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces.
Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time
Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces.
Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Vss of GSK1278863 in Plasma Following IV Dose Administration
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
CL of GSK1278863 in Plasma Following IV Dose Administration
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Absolute Bioavailability of GSK1278863 Following Oral Dosing
Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-8 hours, 10-12 hours in period 2
Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-24 hours in period 2
Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-120 hours in period 2
Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion
The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented.
Time frame: 3 hours post-oral dose in period 1
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.
Time frame: Up to 43 days
Number of Participants With AEs at a Particular Severity
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented.
Time frame: Up to 43 days
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range
Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 43 days
Number of Participants With Worst Case Hematology Results Relative to Normal Range
Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 43 days
Number of Participants With Abnormal Urinalysis Findings
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine.
Time frame: Up to 43 days
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Pre-dose (on Day 1) and Day 8 in treatment period 2; 144 hours (Day 7) in treatment period 1
Change From Baseline in Blood Pressure
Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Change From Baseline in Heart Rate
Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Change From Baseline in Respiratory Rate
Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Change From Baseline in Body Temperature
Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
This study evaluated the excretion balance of daprodustat(GSK1278863) using radiolabeled 14 Carbon \[14C\]-drug substance administered orally, and as an intravenous (IV) infusion, administered as a micro tracer dose (concomitant with an oral, non-radiolabeled dose) in healthy male participants.
| Milestone | All Participants Receiving GSK1278863 |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
| Milestone | All Participants Receiving GSK1278863 |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
| Milestone | All Participants Receiving GSK1278863 |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).
| Hour*nanogram equivalent per milliliter | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.6864 ± 19.8 | 2278.8914 ± 18.2 |
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
No measurements were reported for this outcome.
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour*nanogram equivalent per milliliter | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.5252 ± 18.9 | 2206.7099 ± 18.5 |
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
| Hour*nanogram equivalent per milliliter | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | — | 824.6102 ± 17.2 |
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Nanogram equivalent per milliliter | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 3.0114 ± 15.8 | 623.9059 ± 34.8 |
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
| Nanogram equivalent per milliliter | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | — | 289.9998 ± 30.7 |
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 0.9833 (0.983 to 1.250) | 0.7583 (0.500 to 3.000) |
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
| Hour | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | — | 1.0000 (1.000 to 3.000) |
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.7699 ± 106.4 | 61.8251 ± 15.1 |
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
No measurements were reported for this outcome.
Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters | [14C]-GSK1278863 50 µg IV Infusion |
|---|---|
| Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | 32.2355 ± 59.1 |
Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
No measurements were reported for this outcome.
Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liters per hour | [14C]-GSK1278863 50 µg IV Infusion |
|---|---|
| Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | 7.4779 ± 19.8 |
Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
No measurements were reported for this outcome.
Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration.
| Percent dose excreted | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| Pre-dose; n=6 | 0.000 ± 0.0000 |
| 0-24 hours; n=6 | 20.450 ± 2.7441 |
| 24-48 hours; n=6 | 20.838 ± 2.8280 |
| 48-72 hours; n=6 | 21.003 ± 2.8723 |
| 72-96 hours; n=6 | 21.065 ± 2.8744 |
| 96-120 hours; n=6 | 21.065 ± 2.8744 |
| 120-144 hours; n=6 | 21.065 ± 2.8744 |
| 144-168 hours; n=5 | 21.434 ± 3.0507 |
Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces.
| Percent dose excreted | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| Pre-dose; n=6 | 0.000 ± 0.0000 |
| 0-24 hours; n=5 | 0.096 ± 0.1292 |
| 24-48 hours; n=5 | 22.298 ± 31.0164 |
| 48-72 hours; n=6 | 49.988 ± 25.3857 |
| 72-96 hours; n=6 | 68.312 ± 6.0872 |
| 96-120 hours; n=5 | 73.450 ± 3.1046 |
| 120-144 hours; n=5 | 74.698 ± 2.1027 |
| 144-168 hours; n=4 | 73.553 ± 3.6611 |
Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces.
| Percent dose excreted | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| Pre-dose; n=6 | 0.000 ± 0.0000 |
| 0-24 hours; n=6 | 20.530 ± 2.7223 |
| 24-48 hours; n=6 | 39.433 ± 28.2968 |
| 48-72 hours; n=6 | 70.992 ± 25.9980 |
| 72-96 hours; n=6 | 89.377 ± 6.3351 |
| 96-120 hours; n=6 | 94.177 ± 2.1428 |
| 120-144 hours; n=6 | 94.705 ± 2.0982 |
| 144-168 hours; n=5 | 94.582 ± 2.3066 |
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour*nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses | 199.2552 ± 16.9 | 2.6509 ± 27.4 | 940.2011 ± 28.6 |
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour*nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 198.1658 ± 16.8 | 2.6368 ± 20.4 | 938.5541 ± 28.7 |
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 96.1190 ± 17.2 | 2.0058 ± 25.5 | 544.7022 ± 34.1 |
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.1167 (1.417 to 4.000) | 0.983 (0.983 to 0.983) | 0.5000 (0.500 to 0.517) |
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Hour | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 1.8786 ± 21.6 | 2.0653 ± 6.6 | 2.5037 ± 30.2 |
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Hour*nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| GSK2391220; n=6,0,5 | 33.7699 ± 15.1 | — | 139.7713 ± 19.0 |
| GSK2487818; n=6,0,6 | 21.7209 ± 16.3 | — | 92.0554 ± 16.7 |
| GSK2506102; n=6,0,6 | 8.6207 ± 15.5 | — | 33.1332 ± 15.6 |
| GSK2506104; n=6,0,5 | 34.1180 ± 11.9 | — | 140.3785 ± 16.7 |
| GSK2531398; n=6,0,6 | 15.0285 ± 13.1 | — | 61.7760 ± 15.4 |
| GSK2531401; n=6,0,6 | 34.4699 ± 21.9 | — | 124.1320 ± 25.5 |
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Hour*nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| GSK2391220 | 32.2574 ± 15.0 | — | 142.2907 ± 18.9 |
| GSK2487818 | 21.2933 ± 16.8 | — | 90.9953 ± 16.7 |
| GSK2506102 | 8.0798 ± 14.1 | — | 31.8897 ± 15.9 |
| GSK2506104 | 32.3120 ± 11.9 | — | 142.3372 ± 15.6 |
| GSK2531398 | 14.4743 ± 13.4 | — | 60.2615 ± 15.5 |
| GSK2531401 | 31.7836 ± 18.8 | — | 122.7102 ± 25.8 |
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Nanogram per milliliter | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| GSK2391220 | 7.5219 ± 14.4 | — | 31.5278 ± 30.4 |
| GSK2487818 | 6.0391 ± 19.1 | — | 25.4542 ± 33.0 |
| GSK2506102 | 1.8233 ± 16.6 | — | 6.8139 ± 25.7 |
| GSK2506104 | 7.3607 ± 13.5 | — | 30.4258 ± 27.6 |
| GSK2531398 | 3.5279 ± 12.7 | — | 13.5590 ± 25.8 |
| GSK2531401 | 6.4247 ± 23.6 | — | 21.9493 ± 36.8 |
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Hour | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| GSK2391220 | 3.5000 (2.983 to 6.000) | — | 2.0000 (1.500 to 4.000) |
| GSK2487818 | 3.5000 (1.983 to 6.000) | — | 2.0000 (1.500 to 4.000) |
| GSK2506102 | 3.5000 (2.983 to 6.000) | — | 2.0000 (2.000 to 4.000) |
| GSK2506104 | 4.0000 (2.983 to 6.000) | — | 2.0000 (2.000 to 4.000) |
| GSK2531398 | 3.5000 (2.983 to 6.000) | — | 2.0000 (2.000 to 4.000) |
| GSK2531401 | 4.0000 (3.000 to 6.000) | — | 2.0000 (2.000 to 4.000) |
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Hour | GSK1278863 6 mg Oral Tablet | [14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|---|
| GSK2391220; n=6,0, 5 | 1.9805 ± 7.9 | — | 3.1506 ± 26.1 |
| GSK2487818; n=6,0, 6 | 1.5744 ± 12.5 | — | 1.8644 ± 10.7 |
| GSK2506102; n=6,0, 6 | 2.0037 ± 15.9 | — | 2.2738 ± 5.1 |
| GSK2506104; n=6,0, 5 | 2.0849 ± 8.0 | — | 3.3870 ± 10.9 |
| GSK2531398; n=6,0, 6 | 1.7006 ± 14.7 | — | 1.9767 ± 3.8 |
| GSK2531401; n=6,0, 6 | 2.3217 ± 12.0 | — | 2.9197 ± 9.9 |
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liter | [14C]-GSK1278863 50 µg IV Infusion |
|---|---|
| Vss of GSK1278863 in Plasma Following IV Dose Administration | 14.3387 ± 23.0 |
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
No measurements were reported for this outcome.
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
| Liter per hour | [14C]-GSK1278863 50 µg IV Infusion |
|---|---|
| CL of GSK1278863 in Plasma Following IV Dose Administration | 18.8612 ± 27.4 |
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
No measurements were reported for this outcome.
Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters.
| Ratio of dose normalized AUC | GSK1278863 6 mg Oral Tablet |
|---|---|
| AUC (0-inf); n=3 | 0.6575 ± 11.8 |
| AUC (0-t); n=6 | 0.6263 ± 10.7 |
Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
| Percent radioactivity | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| M2 (GSK2391220) and M33 combined, 0-8 hours | 10.4 |
| M2 (GSK2391220) and M33 combined, 10-12 hours | 14.4 |
| M3 (GSK2506104), 0-8 hours | 7.6 |
| M3 (GSK2506104), 10-12 hours | 11.8 |
| M4 (GSK2487818), 0-8 hours | 5.7 |
| M4 (GSK2487818), 10-12 hours | NA |
| M6 (GSK2531398), 0-8 hours | 3.6 |
| M6 (GSK2531398), 10-12 hours | NA |
| M13 (GSK2531401), 0-8 hours | 8.3 |
| M13 (GSK2531401), 10-12 hours | 16.1 |
| M5 (GSK2506102) and M14 combined, 0-8 hours | 4.5 |
| M5 (GSK2506102) and M14 combined, 10-12 hours | NA |
Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
| Percent radioactivity | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| M2 (GSK2391220) and M33 combined | 15.8 |
| M3 (GSK2506104) | 16.0 |
| M4 (GSK2487818) | 7.9 |
| M6 (GSK2531398) | 5.8 |
| M13 (GSK2531401) | 16.5 |
| M5 (GSK2506102) and M14 combined | 10.4 |
Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
| Percent radioactivity | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|
| M2 (GSK2391220) | 19.8 |
| M3 (GSK2506104) | 14.1 |
| M4 (GSK2487818) | 17.0 |
| M6 (GSK2531398) | 6.2 |
| M13 (GSK2531401) | 4.9 |
| M5 (GSK2506102) and M14 combined | 7.7 |
The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented.
| Percent radioactivity | [14C]-GSK1278863 50 µg IV Infusion |
|---|---|
| M2 (GSK2391220) | 12.3 |
| M3 (GSK2506104) | 20.0 |
| M4 (GSK2487818) | 15.5 |
| M6 (GSK2531398) | 6.3 |
| M13 (GSK2531401) | 2.4 |
| M5 | 11.1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Any AE | 2 | 2 |
| Any SAE | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Mild | 2 | 2 |
| Moderate | 1 | 0 |
| Severe | 0 | 0 |
Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| ALT; To Low | 0 | 0 |
| ALT;To Normal or No Change | 6 | 6 |
| ALT; To High | 0 | 0 |
| Alk Phos; To Low | 0 | 0 |
| Alk Phos; To Normal or No Change | 6 | 6 |
| Alk Phos; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST;To Normal or No Change | 6 | 6 |
| AST; To High | 0 | 0 |
| Bilirubin; To Low | 0 | 0 |
| Bilirubin; To Normal or No Change | 5 | 6 |
| Bilirubin; To High | 1 | 1 |
| Calcium; To Low | 0 | 0 |
| Calcium; To Normal or No Change | 6 | 6 |
| Calcium; To High | 0 | 0 |
| Creatinine; To Low | 0 | 0 |
| Creatinine; To Normal or No Change | 6 | 6 |
| Creatinine; To High | 0 | 0 |
| Direct Bilirubin; To Low | 0 | 0 |
| Direct Bilirubin; To Normal or No Change | 6 | 6 |
| Direct Bilirubin; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To Normal or No Change | 6 | 6 |
| Glucose; To High | 0 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To Normal or No Change | 6 | 6 |
| Potassium; To High | 0 | 0 |
| Protein; To Low | 0 | 0 |
| Protein; To Normal or No Change | 6 | 6 |
| Protein; To High | 0 | 0 |
| Sodium; To Low | 1 | 0 |
| Sodium; To Normal or No Change | 5 | 6 |
| Sodium; To High | 0 | 0 |
| Urea; To Low | 0 | 0 |
| Urea;To Normal or No Change | 6 | 6 |
| Urea; To High | 0 | 0 |
Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Basophils; To Low | 0 | 0 |
| Basophils; To Normal or No Change | 6 | 6 |
| Basophils; To High | 0 | 0 |
| Eosinophils; To Low | 0 | 0 |
| Eosinophils; To Normal or No Change | 6 | 6 |
| Eosinophils; To High | 0 | 0 |
| MCH; To Low | 0 | 0 |
| MCH; To Normal or No Change | 6 | 6 |
| MCH; To High | 0 | 0 |
| MCV; To Low | 0 | 0 |
| MCV; To Normal or No Change | 6 | 6 |
| MCV; To High | 0 | 0 |
| Erythrocytes; To Low | 1 | 0 |
| Erythrocytes; To Normal or No Change | 5 | 6 |
| Erythrocytes; To High | 0 | 0 |
| Hematocrit; To Low | 1 | 1 |
| Hematocrit; To Normal or No Change | 5 | 5 |
| Hematocrit; To High | 0 | 0 |
| Hemoglobin; To Low | 1 | 0 |
| Hemoglobin; To Normal or No Change | 5 | 6 |
| Hemoglobin; To High | 0 | 0 |
| Leukocytes; To Low | 0 | 0 |
| Leukocytes; To Normal or No Change | 6 | 6 |
| Leukocytes; To High | 0 | 0 |
| Lymphocytes; To Low | 1 | 0 |
| Lymphocytes; To Normal or No Change | 5 | 6 |
| Lymphocytes; To High | 0 | 0 |
| Monocytes; To Low | 0 | 0 |
| Monocytes; To Normal or No Change | 6 | 6 |
| Monocytes; To High | 0 | 0 |
| Neutrophils; To Low | 0 | 0 |
| Neutrophils; To Normal or No Change | 6 | 6 |
| Neutrophils; To High | 0 | 0 |
| Platelets; To Low | 0 | 0 |
| Platelets; To Normal or No Change | 6 | 6 |
| Platelets; To High | 0 | 0 |
| Reticulocytes; To Low | 0 | 0 |
| Reticulocytes; To Normal or No Change | 6 | 6 |
| Reticulocytes; To High | 0 | 1 |
| Reticulocytes/Erythrocytes; To Low | 0 | 0 |
| Reticulocytes/Erythrocytes; To Normal or No Change | 6 | 5 |
| Reticulocytes/Erythrocytes; To High | 0 | 2 |
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Number of Participants With Abnormal Urinalysis Findings | 0 | 0 |
Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
| Participants | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Pre-dose (Day 1); n=0,6 | — | 0 |
| 144 hours (Day 7); n= 6, 0 | 0 | — |
| Day 8; n=0, 6 | — | 0 |
Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
| Millimeters of mercury | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| SBP; Avg 3 hours; n=6, 6 | -0.17 ± 5.722 | -1.22 ± 3.468 |
| SBP; Avg 144 hours (Day 7); n=6, 6 | 5.06 ± 10.521 | -2.00 ± 9.541 |
| SBP; Avg Day 8; n=0,6 | — | 4.22 ± 4.075 |
| DBP; Avg 3 hours; n=6, 6 | 1.22 ± 5.484 | 0.89 ± 4.834 |
| DBP; Avg 144 hours (Day 7); n=6, 6 | 3.61 ± 9.365 | -1.00 ± 9.814 |
| DBP; Avg Day 8; n=0,6 | — | 3.39 ± 5.170 |
Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
| Beats per minute | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| Avg 3 hours; n=6, 6 | 0.22 ± 3.526 | 1.67 ± 3.425 |
| Avg 144 hours (Day 7); n=6, 6 | 1.28 ± 6.571 | 3.78 ± 5.500 |
| Avg Day 8; n=0,6 | — | 4.72 ± 5.535 |
Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
| Breaths per minute | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| 3 hours; n=6, 6 | -0.67 ± 2.422 | -0.33 ± 4.082 |
| 144 hours (Day 7); n=6, 6 | -1.33 ± 2.066 | -0.33 ± 1.506 |
| Day 8; n=0,6 | — | 0.00 ± 2.530 |
Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
| Celsius | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| 3 hours; n=6, 6 | 0.08 ± 0.183 | 0.25 ± 0.455 |
| 144 hours (Day 7); n=6, 6 | 0.07 ± 0.446 | 0.12 ± 0.588 |
| Day 8; n=0,6 | — | 0.30 ± 0.693 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 43 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| [14C]-GSK1278863 25 mg Oral Solution | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion | [14C]-GSK1278863 25 mg Oral Solution |
|---|---|---|
| HeadacheNervous system disorders | 1/6 | 1/6 |
| Back painMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 0/6 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/6 | 1/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/6 | 0/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/6 | 1/6 |
| Age, Continuous(Years) | All Participants Receiving GSK1278863 |
|---|---|
| Mean | 40.7 ± 8.57 |
| Sex: Female, Male(Participants) | All Participants Receiving GSK1278863 |
|---|---|
| Female | 0 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | All Participants Receiving GSK1278863 |
|---|---|
| WHITE - ARABIC/NORTH AFRICAN HERITAGE | 1 |
| WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Nov 2017, 1 month.
Results were first posted in Mar 2019, 1 year 3 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 1 month is below that.
Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863